Generics Take a Bite of Eli Lilly Q3 Results

Eli Lilly (NYSE: LLY) this morning reported disappointing third-quarter results as generic drugs took a toll on its sales.

The Indianapolis-based drug maker posted adjusted earnings per share (EPS) of $0.79 on revenues of $5.44 billion. In the same period a year ago, the company reported EPS of $1.13 on revenues of $6.15 billion. The quarter's results also compare to the Thomson Reuters consensus estimates for EPS of $0.83 and $5.62 billion in revenues.

The company's chairman and CEO said:

The third quarter was an eventful one for Lilly, as we gained a better understanding of several potential new medicines in our clinical pipeline, while maintaining focus on delivering solid financial results despite the loss of Zyprexa patent exclusivity.

Also, the company recognized a charge of $53.3 million in the quarter related to asset impairments associated with the decision to stop development of a delivery device platform.

Eli Lilly now expects full-year 2012 EPS to be in the range of $3.30 to $3.40 on revenue of between $21.8 and $22.8 billion. The Thomson Reuters consensus estimates call for EPS of $3.39 and $22.72 billion in revenues.

Shares are inactive in premarket trading but closed yesterday at $51.91. The 52-week range is $35.46 to $53.99.

Filed under: 24/7 Wall St. Wire, Drug companies, Earnings Tagged: LLY
Read Full Story


NASDAQ 7,234.31 -5.16 -0.07%
S&P 500 2,716.26 -15.96 -0.58%
DJIA 24,964.75 -254.63 -1.01%
NIKKEI 225 21,970.81 45.71 0.21%
HANG SENG 31,431.89 558.26 1.81%
DAX 12,410.33 -77.57 -0.62%
USD (per EUR) 1.23 0.00 -0.11%
USD (per CHF) 0.94 0.00 0.15%
JPY (per USD) 107.54 0.17 0.16%
GBP (per USD) 1.39 -0.01 -0.41%

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.